WP
ACER

WealthPLAN Partners’s Acer Therapeutics Inc ACER Stock Holding History

WealthPLAN Partners’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,000
Closed -$759 – 1417
2023
Q1 		$759 Buy
+1,000
New +$1.97K ﹤0.01% 1226

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WealthPLAN Partners's ACER Position: Q2 2023 in Review

WealthPLAN Partners sold out of Acer Therapeutics Inc (ACER) in Q2 2023, closing a stake of 1,000 shares — an estimated $759 sold.

WealthPLAN Partners first reported a position in ACER in Q1 2023 and held it in 1 quarter. The position peaked at $759 in Q1 2023. 28 funds tracked by Wall St. Rank hold ACER as of Q2 2023.

  • WealthPLAN Partners reported no remaining Acer Therapeutics Inc position as of Q2 2023 after selling out during the quarter.
  • WealthPLAN Partners sold 1,000 Acer Therapeutics Inc shares in Q2 2023, an estimated $759.
  • WealthPLAN Partners first reported a position in Acer Therapeutics Inc in Q1 2023 and held it in 1 quarter.
  • WealthPLAN Partners's Acer Therapeutics Inc position peaked at $759 in Q1 2023.
  • 28 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q2 2023.

Based on WealthPLAN Partners's 13F filing for Q2 2023, filed 31 Jul 2023.